Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11141540 | ADAMIS PHARMS CORP | Syringe devices |
Oct, 2036
(13 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 15 June, 2017
Treatment: A method for administering a therapeutic dose of epinephrine
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(15 years from now) | |
US11571518 | ADAMIS PHARMS CORP | NA |
Jun, 2041
(18 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emerge...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic